Compare NTLA & CPRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTLA | CPRI |
|---|---|---|
| Founded | 2014 | 1981 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2016 | 2011 |
| Metric | NTLA | CPRI |
|---|---|---|
| Price | $11.36 | $21.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 15 |
| Target Price | $23.11 | ★ $23.17 |
| AVG Volume (30 Days) | ★ 4.9M | 3.5M |
| Earning Date | 11-17-2026 | 10-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.43 | ★ 111.40 |
| EPS | N/A | ★ 0.85 |
| Revenue | $67,671,000.00 | ★ $3,474,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $143.36 | $2.45 |
| P/E Ratio | ★ N/A | $24.98 |
| Revenue Growth | ★ 16.92 | N/A |
| 52 Week Low | $7.95 | $12.40 |
| 52 Week High | $18.48 | $28.27 |
| Indicator | NTLA | CPRI |
|---|---|---|
| Relative Strength Index (RSI) | 52.25 | 81.01 |
| Support Level | $11.26 | $16.82 |
| Resistance Level | $13.50 | $21.98 |
| Average True Range (ATR) | 0.81 | 0.81 |
| MACD | 0.05 | 0.55 |
| Stochastic Oscillator | 51.49 | 97.55 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 600 company-owned stores, wholesale partners, and online. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold through third-party retailers, e-commerce platforms, and in more than 200 company-operated stores. John Idol has served as Capri's CEO since 2003.